Raleigh Capital Management Inc. Sells 406 Shares of Sanofi (NASDAQ:SNY)

Raleigh Capital Management Inc. lessened its holdings in Sanofi (NASDAQ:SNY) by 1.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,435 shares of the company’s stock after selling 406 shares during the period. Raleigh Capital Management Inc.’s holdings in Sanofi were worth $1,564,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in SNY. Charles Schwab Investment Management Inc. increased its holdings in Sanofi by 31.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after purchasing an additional 33,105 shares during the period. Geode Capital Management LLC raised its holdings in shares of Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. raised its stake in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the period. GFS Advisors LLC raised its holdings in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after buying an additional 11,655 shares during the last quarter. Finally, Icon Wealth Advisors LLC raised its holdings in shares of Sanofi by 7,954.4% in the 3rd quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock worth $16,873,000 after acquiring an additional 289,144 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY opened at $51.51 on Thursday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average price of $48.53 and a 200-day moving average price of $52.16. The company has a market cap of $130.72 billion, a PE ratio of 26.28, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period last year, the firm posted $2.55 EPS. Sanofi’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, equities analysts forecast that Sanofi will post 3.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.